Investigación
Nuestros ensayos clínicos (EECC)
Un EECC es un estudio de investigación en el que se evalúa la seguridad y eficacia de un nuevo fármaco, dispositivo o producto sanitario.
La Unidad colabora estrechamente con todos los servicios del hospital necesarios para asegurar el mejor tratamiento para el paciente.
¿Por qué participar en un ensayo clínico
desde IOR?
Al participar en un EECC en IOR garantizamos una gestión excelente y personalizada de la evolución del paciente, de su tratamiento y de sus necesidades. Contamos con un equipo multidisciplinar con las últimas innovaciones y un laboratorio propio.
Además, para el correcto desarrollo de los protocolos de EECC, contamos con una perfecta coordinación y comunicación entre los doctores que visitan a los pacientes, el personal de enfermería, el personal de coordinación y de farmacia hospitalaria.
Comité ético
El Comité Ético de Investigación Clínica del Hospital Universitario Quirón Dexeus está acreditado por el Ministerio de Sanidad y se reúne con una periodicidad mensual. Su misión es analizar y valorar todas las propuestas de los diferentes Servicios Médicos relativas a programas de investigación, desarrollo y estudio de nuevos fármacos en pacientes, de tal manera que se garantiza el marco ético de protección de los derechos del paciente.
Cada año el Comité evalúa un número importante de ensayos clínicos y proyectos de investigación de diferentes especialidades médicas. Todos y cada uno de nuestros programas de desarrollo clínico han sido evaluados y aprobados por este comité.
Listado de ensayos clínicos
Conoce los ensayos disponibles en la clínica en función del tipo de cáncer.
CNS
CERTIS-1
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)
CNS
TUXEDO-3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
BASKET
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
BASKET
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
BASKET
Transcend IT101
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
BASKET
ASTX727-17
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Severe Renal Impairment and Cancer Patients with Normal Renal Function
BASKET
ASTX727-18
A Phase 1b, Open-label, Parallel Group, Multiple-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Oral Decitabine and Cedazuridine (ASTX727) in Cancer Patients with Moderate and Severe Hepatic Impairment
BASKET
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
BASKET
COMBINE-EGFR-1
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
BASKET
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
BREAST CANCER
EMPRESS
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10% (EMPRESS)
BREAST CANCER
PREMIERE
Estudio fase II, multicéntrico, aleatorizado y abierto de pacientes premenopáusicas con cáncer de mama luminal que investiga el efecto de SERD elacestrant oral con o sin triptorelina en la vía funcional del ER y la proliferación de Ki67. Prueba preoperatoria – PremiÈRe
BREAST CANCER
CAMBRIA-1
A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy With Camizestrant Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients With ER+/HER2- Early Breast Cancer
BREAST CANCER
HARMONIA
A Phase III, multicenter, open-label study of ribociclib vs. palbociclib in patients with advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer
BREAST CANCER
VERITAC-3
Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer (VERITAC-3)
BREAST CANCER
pionERA
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
BREAST CANCER
PIKASSO-01
A Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation
BREAST CANCER
eVERA
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician’s Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
BREAST CANCER
ARV-471-mBC-102
A Phase 1b Trial of ARV-471 in Combination with Everolimus in Patients with ER+, HER2– Advanced or Metastatic Breast Cancer
BREAST CANCER
C4891006
TACTIVE-U: An interventional safety and efficacy Phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of vepdegestrant (ARV-471/PF-07850327), an oral Proteolysis Targeting Chimera, in combination with other anticancer treatments in participants Aged 18 years and Over with ER+ advanced or Metastatic breast cancer, Sub-study A (ARV-471 in combination with Abemaciclib)
BREAST CANCER
C4891006
TACTIVE-U: An interventional safety and efficacy Phase 1b/2, open-label umbrella study to investigate tolerability, pk, and antitumor activity of vepdegestrant (ARV-471/PF-07850327), an oral Proteolysis Targeting Chimera, in combination with other anticancer treatments in participants Aged 18 years and Over with ER+ advanced or Metastatic breast cancer, Sub-study B (ARV-471 in combination with Ribociclib)
BREAST CANCER
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
BREAST CANCER
CERTIS-1
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)
BREAST CANCER
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
BREAST CANCER
WO44263 Inavo122
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
BREAST CANCER
TROPION Breast03
A Study of Dato-DXd With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)
BREAST CANCER
ASCENT-3
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
BREAST CANCER
ASCENT-4
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-04)
BREAST CANCER
CERTIS-1
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)
BREAST CANCER
CERTIS-1
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (CERTIS1)
BREAST CANCER
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
DIGESTIVE
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
DIGESTIVE
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
DIGESTIVE
COMBINE-EGFR-1
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
DIGESTIVE
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
DIGESTIVE
SYRACUSA
A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination with Anti-Cancer Agents in Adult Participants with Metastatic Pancreatic Adenocarcinoma
DIGESTIVE
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
ENDOCRINE
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
ENDOCRINE
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
GYNECOLOGICAL
NIRVANA
SL03-OHD-105 is an open-label, multicenter, phase 1b trial designed to evaluate SL-172154 administered in combination with pegylated liposomal doxorubicin (PLD) or mirvetuximab soravtansine (MIRV) in patients with platinum resistant ovarian cancer. Approximately 102 patients will be enrolled in this study in two phases: dose escalation and dose expansion.
GYNECOLOGICAL
IMGN853-0420
Multicenter, Open-label, ph 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
GYNECOLOGICAL
SL0-OHD-105
An Open-Label, Phase 1b Study of SL-172154 (SIRPα-Fc-CD40L) Administered With Either Pegylated Liposomal Doxorubicin or Mirvetuximab Soravtansine in Subjects With Platinum-Resistant Ovarian Cancer
GYNECOLOGICAL
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
GYNECOLOGICAL
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
GYNECOLOGICAL
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
GYNECOLOGICAL
Transcend IT101
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
GYNECOLOGICAL
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
HEAD AND NECK
IO102-IO103-032
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
HEAD AND NECK
ASPEN-03
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)
HEAD AND NECK
ASPEN-04
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)
HEAD AND NECK
SGNTV-001
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors (innovaTV 207)
HEAD AND NECK
Transcend IT101
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
HEAD AND NECK
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
HEAD AND NECK
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
HEAD AND NECK
IMGN853-0420
Multicenter, Open-label, ph 2 Study of Carboplatin Plus Mirvetuximab Soravtansine Followed by Mirvetuximab Soravtansine Continuation in FRα Positive, Recurrent Platinum-sensitive, High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Following 1 Prior Line of Platinum-based Chemotherapy
HEAD AND NECK
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
HEAD AND NECK
COMBINE-EGFR-1
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
HEAD AND NECK
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
LUNG CANCER
NADIM ADJUVANT
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy (NADIM-ADJUVANT)
LUNG CANCER
DUMAS
Phase II clinical trial of Neo-adjuvant chemo/immunotherapy followed by adjuvant treatment depending on the resection status for the treatment of NSCLC patients diagnosed with pancoast tumor. A multicenter exploratory study
LUNG CANCER
COMBINE-EGFR-1
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
LUNG CANCER
86974680NSC1001
A Phase 1 Study of JNJ-86974680, an A2a Receptor Antagonist, Administered as Monotherapy and in Combination With Cetrelimab and Radiotherapy for Advanced Non-small Cell Lung Cancer
LUNG CANCER
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
LUNG CANCER
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
LUNG CANCER
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
LUNG CANCER
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
LUNG CANCER
NEO DIANA
A Phase II Trial of Neoadjuvant Treatment Carboplatin-Pemetrexed-Bevacizumab Plus Atezolizumab for the Treatment of Locally Advanced and Potentially Resectable NSCLC Patients With EGFR Mutations
LUNG CANCER
COCOON
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib (COCOON)
LUNG CANCER
CHRISALIS-2
An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants With Advanced Non-Small Cell Lung Cancer
LUNG CANCER
TOTEM
Phase I Clinical Study to Assess Safety and Efficacy of Repotrectinib Combined With Osimertinib in Patients With Advanced, Metastatic EGFR Mutant NSCLC (TOTEM).
LUNG CANCER
WU-KONG
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon20 Insertion Mutation
LUNG CANCER
BAY-2927088 21607
First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)
LUNG CANCER
LIBRETTO-431 MC- JCJC
A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LUNG CANCER
MERIT-LUNG
Phase II Clinical Trial of AMG510 (Sotorasib) in Stage III Unresectable NSCLC KRAS p.G12C Patients and Medically Ineligible for Concurrent Chemo-radiotherap
LUNG CANCER
SUNRAY01
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression
LUNG CANCER
KRISTAL-7
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients KRAS G12C Mutation KRYSTAL-7
LUNG CANCER
M18-868
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
LUNG CANCER
SUNRAY01
SUNRAY-01, A Global Pivotal Study in Participants with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of LY3537982 and Pembrolizumab vs Placebo and Pembrolizumab in those with PD-L1 expression ≥50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 Expression
LUNG CANCER
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
MELANOMA & SKIN
Transcend IT101
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
MELANOMA & SKIN
IO102-IO103-032
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
MELANOMA & SKIN
Regeneron 2055
A Phase 3 Trial of Fianlimab (Anti-LAG-3) and Cemiplimab Versus Pembrolizumab in the Adjuvant Setting in Patients With Completely Resected High-risk Melanoma
MELANOMA & SKIN
Regeneron 2011
A Phase 2 and Phase 3 Trial of Fianlimab (REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
MELANOMA & SKIN
IOV-MEL-301
A study to investigate the efficacy and safety of the lifileucel (LN-144, autologous tumor- infiltrating lymphocytes [TIL]) regimen plus pembrolizumab infusions compared with pembrolizumab infusions alone in participants with untreated, unresectable or metastatic melanoma
MELANOMA & SKIN
KN-8701
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants with BRAF and/or NRAS Mutation-positive Solid Tumors
MELANOMA & SKIN
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
MELANOMA & SKIN
Transcend IT101
A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors
MELANOMA & SKIN
COMBINE-EGFR-1
A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination With Cemiplimab in Patients With Advanced Solid Tumors
UROLOGICAL
PYX-106-101
A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PYX‐106 in Subjects with Advanced Solid Tumors
UROLOGICAL
TAK.280.1501
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
UROLOGICAL
JEWEL-101
A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 As Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors
UROLOGICAL
TUXEDO- 3
A Multicenter, Single-arm, Three Cohort, Phase II Trial Of Patritumab Deruxtecan (Her3-dxd) In Patients With Active Brain Metastases From Metastatic Breast Cancer And Non–small Cell Lung Cancer, And In Patients With Leptomeningeal Carcinomatosis From Advanced Solid Tumors
(Pendiente recibir listado de ensayos clínicos.)
CÁNCER COLORRECTAL
XILONIX
CÁNCER DE MAMA
1200.75 (BIBW 2992)
CÁNCER DE MAMA
LORELEI
CÁNCER DE MAMA
LUX-Breast 1
CÁNCER DE MAMA
MANTA
CÁNCER DE MAMA
PAMELA
CÁNCER DE OVARIO
1199.15
CÁNCER DE OVARIO
GEICO 1402-R
CÁNCER DE PULMÓN Y PLEURA
ARIAD ALTA-1
Estudio de fase III abierto y multicéntrico de brigatinib (AP26113) frente a crizotinib en pacientes con cáncer de pulmón avanzado ALK-positivo. Protocolo: AP26113-13-301.
CÁNCER DE PULMÓN Y PLEURA
ATALANTE1
CÁNCER DE PULMÓN Y PLEURA
AZENT
Ensayo clínico de fase IIa de la seguridad y eficacia de AZD9291 en pacientes sin tratamiento previo para enfermedad avanzada con cáncer de pulmón no microcítico EGFR mutado concomitante con presencia de la mutación EGFR T790M al diagnóstico. Protocolo: MedOPP112